PMID- 20689467
OWN - NLM
STAT- MEDLINE
DCOM- 20100928
LR  - 20220408
IS  - 1541-8243 (Electronic)
IS  - 0038-4348 (Linking)
VI  - 103
IP  - 9
DP  - 2010 Sep
TI  - Improved quality of life, immunoglobulin G levels, and infection rates in 
      patients with primary immunodeficiency diseases during self-treatment with 
      subcutaneous immunoglobulin G.
PG  - 856-63
LID - 10.1097/SMJ.0b013e3181eba6ea [doi]
AB  - OBJECTIVES: Primary immunodeficiency diseases (PIDDs) include a large class of 
      genetically heterogeneous disorders which predispose patients to significant risk 
      of serious and chronic/recurrent infections, as well as reduced quality of life 
      (QoL). Intravenous immunoglobulin (IVIG) therapy improves the well being of PIDD 
      patients; however, the need for venous access and potentially severe side effects 
      frequently require administration in medical facilities. We evaluated the 
      long-term (12-month) experience with home-based self infusions of subcutaneous 
      immune globulin (SCIG) in patients with PIDD on health-related QoL, rates of 
      serious bacterial infections, and all other infections. METHODS: Adults (n = 42) 
      and children (n = 9) with PIDD, previously treated with clinic-based IVIG, were 
      trained to self administer SCIG at home. QoL (SF-36(R) and CHQ-PF50 
      questionnaires), serious bacterial infections, serum immunoglobulin G (IgG) 
      levels, overall infections, and incidence of adverse events were recorded at 
      predetermined intervals. RESULTS: All patients had improved perceptions of 
      general health (adults P = 0.047, children P = 0.037). Adults also had marked 
      improvement in the bodily pain and vitality assessments, and parents had improved 
      perceptions of personal and family activities. Serum IgG levels were maintained 
      at mean levels 25% higher than previous troughs on IVIG. There were 162 
      infections overall for an annual rate of 3.42/patient, but only 1 serious 
      bacterial infection was observed (0.03/patient/yr). An average of 4.5 days/yr was 
      missed from work or school per patient. CONCLUSIONS: Home SCIG therapy was safe 
      and led to improved perceptions of general health, higher serum IgG levels, and 
      very low rates of infections and days missed from work/school.
FAU - Berger, Melvin
AU  - Berger M
AD  - Medical Affairs Department CSL Behring, King of Prussia, PA, USA. 
      mel.berger@cslbehring.com
FAU - Murphy, Elyse
AU  - Murphy E
FAU - Riley, Patty
AU  - Riley P
FAU - Bergman, Garrett E
AU  - Bergman GE
CN  - VIRTUE Trial Investigators
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - South Med J
JT  - Southern medical journal
JID - 0404522
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulins)
RN  - 0 (Immunologic Factors)
RN  - 0 (Vivaglobin)
SB  - IM
CIN - South Med J. 2010 Sep;103(9):851-2. PMID: 20689488
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Child
MH  - Child, Preschool
MH  - Drug Eruptions
MH  - Female
MH  - Health Status
MH  - Humans
MH  - Immunoglobulin G/blood
MH  - Immunoglobulins/*administration & dosage/adverse effects
MH  - Immunologic Deficiency Syndromes/*drug therapy
MH  - Immunologic Factors/*administration & dosage/adverse effects
MH  - Infections/epidemiology
MH  - Infusions, Subcutaneous
MH  - Male
MH  - Mental Health
MH  - Middle Aged
MH  - *Quality of Life
MH  - Self Administration
MH  - Sick Leave
EDAT- 2010/08/07 06:00
MHDA- 2010/09/30 06:00
CRDT- 2010/08/07 06:00
PHST- 2010/08/07 06:00 [entrez]
PHST- 2010/08/07 06:00 [pubmed]
PHST- 2010/09/30 06:00 [medline]
AID - 10.1097/SMJ.0b013e3181eba6ea [doi]
PST - ppublish
SO  - South Med J. 2010 Sep;103(9):856-63. doi: 10.1097/SMJ.0b013e3181eba6ea.